Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

NCT03004001 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

FED

Sponsor class

Stopped Difficult recruitment

Conditions

Nephrotic Syndrome

Interventions

DRUG: Alirocumab
DRUG: Alirocumab placebo
DRUG: Atorvastatin

Sponsor

Gloria Vega

Collaborators

[object Object]
[object Object]